SAN MATEO, Calif.--(BUSINESS WIRE)--Bayhill Therapeutics Inc. announced today that it has entered into an exclusive worldwide license agreement for the development and potential commercialization of BHT-3021 with Genentech, Inc. a wholly-owned member of the Roche Group. BHT-3021 is Bayhill’s DNA based antigen specific immunotherapy currently in a phase I/II clinical trial in patients with type 1 diabetes (T1D).
Bayhill Therapeutics enters exclusive, worldwide collaboration with Genentech for BHT-3021 in Type 1 diabetes
TargeGen successfully completed enrollment of a multi-center clinical trial of TG101348
SAN DIEGO, May 14, 2009 /PRNewswire/ -- TargeGen, Inc. today announced that the Company successfully completed enrollment of a multi-center clinical trial of TG101348, an oral, potent, and highly selective inhibitor of JAK2 in patients with myelofibrosis on May 7, 2009.
Tyrx presents early clinical results from AIGISRXTM antibacterial envelope retrospective registry
Monmouth, NJ, (May 22, 2009) -- TYRX, Inc., a leader in the commercialization of implantable medical-pharmaceutical devices announced today at the 30th Annual Scientific Sessions of the Heart Rhythm Society the initial, interim clinical results from its AIGISRXTM Antibacterial Envelope Retrospective Registry.
Anthera's varespladib meets primary endpoint in phase 2 FRANCIS trial for the treatment of Acute Coronary Syndrome
- Favorable results for secondary endpoints support outcomes benefit
HAYWARD, CA – May 6, 2009 – Anthera Pharmaceuticals, Inc., a privately held biopharmaceutical company developing anti-inflammatory drugs, announced today that FRANCIS (Fewer Recurrent Acute coronary events with Near-term Cardiovascular Inflammation Suppression), a clinical trial designed to examine the impact of 500mg of varespladib when administered to patients within 96 hours of an Acute Coronary Syndrome (ACS) event, met its primary endpoint of a reduction in Low Density Lipoprotein Cholesterol (LDL-C). All patients in the FRANCIS trial received once daily doses of 80mg of Lipitor® (atorvastatin calcium), plus 500mg of varespladib or matching placebo. Varespladib is a potent and highly selective oral inhibitor of secretory phospholipase A2 (sPLA2), an inflammatory enzyme implicated in ACS, vascular inflammation, atherosclerosis and adverse lipid profiles.
Cardiac "Jackhammer" Destroys Arterial Plaque
LAKEWOOD RANCH, March 30, 2009 — Lakewood Ranch Medical Center is the first acute care center in the area to offer a new high-tech procedure that can take the place of bypass surgery for some patients.
A vibrating catheter blasts its way through stoney plaque deposits the same way a jackhammer cuts through concrete, says Dr. Erick E. Calderon, of Lakewood Cardiovascular Consultants, one of the first doctors in Florida trained to use the new device.
Anthera to continue impacts trial for the prevention of acute chest syndrome in patients with sickle cell disease
Anthera Pharmaceuticals, Inc., a privately held biopharmaceutical company developing anti-inflammatory drugs, announced today that after completing its review of safety and efficacy data from the first cohort of 30 patients, an independent Data Safety Monitoring Board (DSMB) has recommended that Anthera’s Phase II clinical trial, known as the IMPACTS (Investigation of the Modulation of Phospholipase in Acute ChesT Syndrome) Study can continue under the current protocol based on favorable interim results.
Pappas Ventures closes on fourth fund
RESEARCH TRIANGLE PARK, N.C., March 10, 2009 — Pappas Ventures today announced the final closing of its fourth fund, a $102 million venture capital fund focused on the life sciences sector. Like its immediate predecessor funds, Pappas Ventures IV will invest in product-oriented biopharmaceutical companies, with a secondary focus on medical technologies.
Genstruct and Gene Logic collaborate on systems toxicology
SAN FRANCISCO, CAMBRIDGE, Mass. and GAITHERSBURG, Md., Feb. 25 /PRNewswire/ -- Genstruct Inc., a systems biology company focused on identifying molecular mechanisms, networks and biomarkers to better develop novel therapeutics, molecular diagnostics and patient-specific therapies, today announced that it has signed a partnership agreement with Gene Logic, an Ocimum Biosolutions company, for a systems toxicology collaboration.
Cequent releases primate safety, efficacy data for oral FAP therapy
February 12, 2009
Cequent Pharmaceuticals this week unveiled non-human primate data demonstrating the safety and gene-silencing ability of its lead drug candidate, a treatment for familial adenomatous polyposis dubbed CEQ501, in what the company is calling the first proof of activity of an oral RNAi drug.
Plexxikon and Roche enter second partnership
Berkeley, CA and Basel, Switzerland - January 8, 2009 -- Plexxikon Inc. and Roche (SWX:ROG), today announced that they have entered into an agreement to develop and commercialize a second novel kinase inhibitor, PLX5568. The main focus of this partnership will be the development of this small molecule inhibitor of Raf kinase as an oral therapeutic treatment for polycystic kidney disease (PKD). There is currently no registered treatment for PKD which affects over 600,000 patients in the U.S and is the most common life- threatening genetic disease.
